Personalized Treatment of Urogenital Cancers Depends on the Microbiome

Last updated: January 28, 2024
Sponsor: Zealand University Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Urologic Cancer

Treatment

Placebo

Tigecycline 50 MG

Clinical Study ID

NCT03962920
ZUHURO
  • Ages 40-70
  • All Genders

Study Summary

This is a randomized controlled trial where patients undergoing surgical treatment for urogenital cancers will be randomized in a two arms study: surgical treatment + antibiotics OR surgical treatment + placebo.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Biopsy verified diagnosis of urological cancer, localized disease

Exclusion

Exclusion Criteria:

  • Hospitalization within three months of surgery
  • Antibiotics within three months of surgery
  • Infectious disease, including UTI's within three months of surgery
  • History of cancers of the genitourinary tract
  • Diabetes

Study Design

Total Participants: 28
Treatment Group(s): 2
Primary Treatment: Placebo
Phase:
Study Start date:
May 01, 2020
Estimated Completion Date:
May 01, 2027

Connect with a study center

  • Zealand University Hospital

    Roskilde, 4000
    Denmark

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.